Regulatory
AHRM Inc’s experience with US Regulatory Regulatory Affairs and Clinical Research Services allow us to provide our clients with the following:
Provide FDA regulatory strategy for device development and device classification
- Act as FDA liaison
- Submit your study protocol to FDA for a Pre-IDE review
- Conduct pre-submission meetings
- Work with the FDA to resolve any issues with the study approach
- Provide advice and assistance and acts as a direct or indirect liaison between your company and FDA
- Assist with clinical FDA negotiations meetings
- Assist with device labeling requirements
- Provide advice and support for preparation of 510(k), Investigational Device Exemptions (IDE), and Pre-market Approval (PMA) and CE Mark submissions and post-market requirements
- Help or prepare you for FDA Advisory Committee meetings or physician advisory meetings
- Assist with Import/Export Issues
- Access to Global Network of Regulatory Affairs Experts: specifically China, India, Canada, UK and Latin America
Client Testimonial
AHRM, Inc. thank you so much for developing such a great web-site. The eCRF is the best that I have used. Your eCRF is arranged in a logical manner, which makes adding data a breeze. The drop-down menus have very explicit options, which I am sure will help streamline the data for the statisticians and definitely saves me time with data entry.
I am always impressed with the speed the pages load and the reliability of the web-site. I also like the interface between the Coordinator Site and the Pharmacy Site. This added electronic communication really helps with late-night randomization and dosing. I really like the tab created for adverse events. With a large interventional study with critically ill patients, there are a lot of adverse events. Having a quick, easy way to enter these events has made the chore much more tolerable.
Thank you for saving me time (which is always in short supply) with your friendly eCRF.
Melissa Lamb
Research Coordinator
University of Florida
Pediatric Critical Care